Mortality Risk for Docetaxel-Treated, High-Grade Prostate Cancer With Low PSA Levels

Overview of attention for article published in JAMA Network Open, November 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
Good Attention Score compared to outputs of the same age and source (66th percentile)

Mentioned by

news: 9 news outlets
blogs: 1 blog

twitter: 13 X users
facebook: 1 Facebook page

Readers on

mendeley: 21 Mendeley

So far, Altmetric has seen 9 news stories from 9 outlets.

Docetaxel Improves Prostate Cancer-Specific Survival in Certain Patients

Renal & Urology News, 12 Nov 2024

Adding docetaxel to standard treatment can prolong prostate cancer-specific survival in certain patients, according to a meta-ana…

Docetaxel/SOC Significantly Reduces Mortality in Low PSA Prostate Cancer

Cancer Network, 07 Nov 2023

"[Docetaxel plus standard of care yields] a marked improvement in survival for these patients, who currently do not have any…

Docetaxel Improves Prostate Cancer-Specific Survival in Certain Patients

Cancer Therapy Advisor, 07 Nov 2023

Adding docetaxel to standard treatment can prolong prostate cancer-specific survival in certain patients, according to a meta-ana…

Neues zum Mamma-, Prostata- und Urothelkarzinom sowie zum B-Zell-Lymphom

Medscape, 06 Nov 2023

Im Onko-Blog dieser Woche berichten wir unter anderem, dass eine vaginale Östrogentherapie bei Frauen mit Mammakarzinom das…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 5 additional news stories.